Context Therapeutics Inc (6K9.BE)

Berlin - Berlin Delayed Price. Currency in EUR

1.2900

-0.0700

(-5.15%)

At close: 09:40PM CEST

Advertisement

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	1.3600
Open	1.4300
Bid	1.3000 x N/A
Ask	1.4000 x N/A
Day's Range	1.2800 - 1.4300
52 Week Range	0.4360 - 1.5200
Volume	3,350
Avg. Volume	0

Market Cap	N/A
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 6K9.BE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA. Details of the presenta
News Direct
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76.
GlobeNewswire
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming

Advertisement

S&P 5004,288.39+0.34(+0.01%)

Dow 3033,433.35-74.15(-0.22%)

Nasdaq13,307.77+88.45(+0.67%)

Russell 20001,756.82-28.28(-1.58%)

Crude Oil88.63-0.19(-0.21%)

Gold1,844.30-2.90(-0.16%)

Context Therapeutics Inc (6K9.BE)

Chart Events

Performance Outlook

Fair Value

Related Research

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

S&P 500
4,288.39
+0.34(+0.01%)

Dow 30
33,433.35
-74.15(-0.22%)

Nasdaq
13,307.77
+88.45(+0.67%)

Russell 2000
1,756.82
-28.28(-1.58%)

Crude Oil
88.63
-0.19(-0.21%)

Gold
1,844.30
-2.90(-0.16%)